{"id":1048,"date":"2023-04-28T11:14:14","date_gmt":"2023-04-28T10:14:14","guid":{"rendered":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/?p=1048"},"modified":"2023-04-28T11:14:15","modified_gmt":"2023-04-28T10:14:15","slug":"brivudina-interaccions-potencialment-mortals","status":"publish","type":"post","link":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/brivudina-interaccions-potencialment-mortals\/","title":{"rendered":"Brivudina: interaccions potencialment mortals"},"content":{"rendered":"\n<p>L&#8217;AEMPS publica una nova <a href=\"https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2023\/NI_MUH_FV-3-2023-Brivudina.pdf\">nota informativa<\/a> en la que es fa un recordatori sobre el risc d&#8217;interacci\u00f3 entre brivudina i fluoropirimidines (com ara capecitabina, 5-fluorouracil, tegafur, floxuridina, flucitosina). Es tracta d&#8217;una interacci\u00f3 que pot ser potencialment mortal i mai no s&#8217;han d&#8217;administrar simult\u00e0niament.<\/p>\n\n\n\n<p>La brivudina \u00e9s un antiv\u00edric autoritzat en el tractament de la infecci\u00f3 per herpes z\u00f3ster en adults immunocompetents. A la fitxa t\u00e8cnica del producte s&#8217;especifica de manera detallada aquesta interacci\u00f3 i els riscos potencials.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft size-full is-resized\"><img loading=\"lazy\" src=\"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-content\/uploads\/sites\/5\/2023\/04\/logo-aemps.png\" alt=\"\" class=\"wp-image-1049\" width=\"520\" height=\"104\" \/><\/figure><\/div>\n\n\n<p>Tot i les mesures informatives i de minimitzaci\u00f3 de riscos dutes a terme fins ara (veure notes informatives <a href=\"https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2012\/docs\/NI-MUH_FV_07-2012.pdf\">MUH (FV), 7\/2012<\/a> i <a href=\"https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2017\/docs\/NI-MUH_FV_09-2017-brivudina-Nervinex.pdf\">MUH (FV), 09\/2017)<\/a>, se segueixen notificant casos greus, incloent casos amb desenlla\u00e7 mortal, derivats de l&#8217;\u00fas concomitant de brivudina i fluoropirimidines.<\/p>\n\n\n\n<p>En aquesta situaci\u00f3, es fan les seg\u00fcents recomanacions:<\/p>\n\n\n\n<p>-S&#8217;ha de respectar un per\u00edode d&#8217;espera com a m\u00ednim de 4 setmanes entre la finalitzaci\u00f3 del tractament amb brivudina i l&#8217;inici de l&#8217;administraci\u00f3 de fluoropirimidines.<br>-\u00c9s indispensable que abans de prescriure brivudina, el professional m\u00e8dic s&#8217;asseguri que el pacient no est\u00e0 rebent quimioter\u00e0pia antineopl\u00e0ssica que contingui 5-fluoropirimidines o flucitosina.<br>-En dispensar brivudina cal informar el pacient i recordar-li que llegiu detingudament l&#8217;advert\u00e8ncia i la targeta d&#8217;informaci\u00f3 inclosa a l&#8217;env\u00e0s, a m\u00e9s del prospecte.<br><\/p>\n\n\n\n<p>Hi ha a disposici\u00f3 dels professionals sanitaris un <a href=\"https:\/\/cima.aemps.es\/cima\/DocsPub\/15\/2739\">document informatiu que inclou una llista de comprovaci\u00f3 per al metge prescriptor<\/a> a m\u00e9s de la <a href=\"https:\/\/cima.aemps.es\/cima\/DocsPub\/16\/2312\">targeta d&#8217;informaci\u00f3 per al pacient<\/a> inclosa a l&#8217;env\u00e0s del medicament.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;AEMPS publica una nova nota informativa en la que es fa un recordatori sobre el risc d&#8217;interacci\u00f3 entre brivudina i fluoropirimidines (com ara capecitabina, 5-fluorouracil, tegafur, floxuridina, flucitosina). Es tracta d&#8217;una interacci\u00f3 que pot ser potencialment mortal i mai no &hellip; <a href=\"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/brivudina-interaccions-potencialment-mortals\/\">Continua llegint <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[19],"tags":[1118,149,1114,1113,242,1057,1120,1121,1117,1115,1116,615,331,1119],"_links":{"self":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/posts\/1048"}],"collection":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/comments?post=1048"}],"version-history":[{"count":1,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/posts\/1048\/revisions"}],"predecessor-version":[{"id":1050,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/posts\/1048\/revisions\/1050"}],"wp:attachment":[{"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/media?parent=1048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/categories?post=1048"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blogs.bellvitgehospital.cat\/farmacologiaclinica\/wp-json\/wp\/v2\/tags?post=1048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}